Relay Therapeutics (RLAY) Non Operating Income (2020 - 2026)
Relay Therapeutics (RLAY) posted quarterly Non Operating Income of $30000.0 for Q4 2025, up 2900.0% year-over-year from $1000.0 in Q4 2024, and up 118.18% quarter-over-quarter from -$165000.0 in Q3 2025.
Powered by 
Analysis
Relay Therapeutics (RLAY) Non Operating Income (2020 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Non Operating Income for 6 consecutive years, with $30000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income rose 2900.0% year-over-year to $30000.0; the TTM figure through Dec 2025 stood at -$777000.0 (down 5650.0% YoY), while the FY2025 annual figure was -$776000.0, down 5642.86% from the prior year.
- Non Operating Income grew to $30000.0 in Q4 2025 per RLAY's latest filing, from -$165000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $30000.0 in Q4 2025 and bottomed at -$633000.0 in Q2 2025.
- Historically, Non Operating Income has averaged -$44722.2 across 5 years, with a median of -$2500.0 in 2023.
- On a YoY basis, Non Operating Income climbed as much as 2900.0% in 2025 and fell as far as 31550.0% in 2025.
- Relay Therapeutics' Non Operating Income stood at $1000.0 in 2021, then sank by 2500.0% to -$24000.0 in 2022, then surged by 104.17% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then soared by 2900.0% to $30000.0 in 2025.
- Business Quant data shows RLAY's Non Operating Income at $30000.0 in Q4 2025, -$165000.0 in Q3 2025, and -$633000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Relay Therapeutics | 3.85 Bn | 3.85 Bn | - | 2,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | -165,000.00 |
| Jun 30, 2025 | -633,000.00 |
| Mar 31, 2025 | -9,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | -10,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | 25,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | -2,000.00 |
| Jun 30, 2023 | -14,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Dec 31, 2022 | -24,000.00 |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 18,000.00 |
| Mar 31, 2022 | -21,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | -5,000.00 |
| Dec 31, 2020 | -8,000.00 |